Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy (vol 35, pg 709, 2017)

被引：2
作者：
Naidoo
Long, Georgina
Hellmann, Matthew
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 22期
关键词：
D O I：
10.1200/JCO.2017.74.5042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2590 / 2590
页数：1
相关论文
共 50 条
  • [21] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Lee, Yong Jun
    Lee, Jii Bum
    Ha, Sang-Jun
    Kim, Hye Ryun
    MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
  • [22] Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature
    Tsiogka, Aikaterini
    Bauer, Johann W.
    Patsatsi, Aikaterini
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 1 - 7
  • [23] Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
    Tang, Kimberly
    Seo, Jayhyun
    Tiu, Bruce C.
    Le, Thomas K.
    Pahalyants, Vartan
    Raval, Neel S.
    Ugwu-Dike, Pearl O.
    Zubiri, Leyre
    Naranbhai, Vivek
    Carrington, Mary
    Gusev, Alexander
    Reynolds, Kerry L.
    LeBoeuf, Nicole R.
    Asgari, Maryam M.
    Kwatra, Shawn G.
    Semenov, Yevgeniy R.
    JAMA DERMATOLOGY, 2022, 158 (02) : 189 - 193
  • [24] Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients
    Yun, Jenny S. W.
    Chan, On Bon
    Goh, Michelle
    McCormack, Christopher J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (01) : 131 - 137
  • [25] Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-Programmed Cell Death Ligand 1 Therapy: A Case Series
    Yun, Jenny Sung Won
    Chan, Louis
    Goh, Michelle
    McCormack, Chris
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 18 - 18
  • [26] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    慢性疾病与转化医学（英文）, 2019, 5 (03) : 170 - 177
  • [27] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns Reply
    Naidoo, Jarushka
    Iyriboz, Tunc
    Cunningham, Jane
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1629 - +
  • [28] Risk factors for pneumonitis in solid tumors treated with anti-programmed death-1 therapy: A case-control study.
    Cui, Pengfei
    Liu, Zhefeng
    Wang, Guoqiang
    Ma, Junxun
    Qian, Yuanyu
    Zhang, Fan
    Han, Chun
    Long, Yaping
    Li, Ye
    Zheng, Xuan
    Sun, Danyang
    Zhang, Jing
    Cai, Shangli
    Jiao, Shun Chang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils
    Zhao, Cathy Yunjia
    Consuegra, Germana
    Chou, Shaun
    Fernandez-Penas, Pablo
    MELANOMA RESEARCH, 2017, 27 (06) : 641 - 644
  • [30] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma (vol 27, pg 384, 2015)
    Cheah, C. Y.
    Fowler, N. H.
    Neelapu, S. S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (06) : 568 - 568
12345